PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
3110.63%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
11227.11%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
26362.71%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
-84.19%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-40.83%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-16129.65%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
-16129.65%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-12933.18%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
24.22%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
24.22%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.